Shahin Rafii, Ph.D.

Dr. Rafii is the Arthur B. Belfer Professor of Genetic Medicine at Weill-Cornell Medical College. Dr. Rafii, who is a board certified Hematologist-Oncologist, is engaged in patient care, and basic and translational research. He has expertise in basic tumor biology as well as vascular and stem cell biology. He was recently appointed to spearhead the Ansary Stem Cell Center for Regenerative Medicine at Weill-Cornell.

Dr. Rafii graduated from Cornell University in 1982, with a degree of Cum Laude in Chemistry and was awarded Phi Beta Kappa. He received his MD degree from Albert Einstein College of Medicine with Honors and was elected to AOA society in 1986. Subsequently, in 1989, he completed his internship and residency in Internal Medicine followed by a fellowship in Hematology-Oncology at Weill-Cornell in 1992. By 1996, he completed his post-doctoral training in vascular and hematopoietic stem cell biology under supervision of Dr. Ralph Nachman at Weill-Cornell. He became a full professor in Genetic Medicine in 2002, at which time he was appointed to be the co-director of the Ansary Stem Cell Center.

Dr. Rafii is funded by multiple R01 grants from the NIH's Heart, Lung and Blood Institute, and is an active charter member of the Tumor Microenvironment Study Section at the National Cancer Institute. He is an elected member of the American Society of Clinical Investigation (Young Turks), an American Cancer Society Scholar, and a Translational Researcher of the Leukemia and Lymphoma Society.

He has organized Keystone conferences, and actively participates in stem cell meetings both in the U.S.A., and internationally. He has trained many post-doctoral graduate students, and others, resulting in being appointed to independent tenure track positions in the U.S.A., Europe, and Japan. He is a consulting editor for the Journal of Clinical Investigation and is a member of Editorial Board of Stem Cells Journal and Journal of Cardiovascular Regeneration.

Dr. Rafii is principal inventor in several patents on therapeutic use of vascular stem cells for organ regeneration. Many of his basic science findings have endured the scrutiny of scientific enquiry and have been translated into the clinical arena.

Malcom A.S. Moore, D.Phil.

Dr. Moore has served as our medical advisor since July 2002. He is Professor of Biology at the Memorial Sloan Kettering Cancer Institute, Cornell Graduate School of Medical Sciences. He is the Director of the Gar Reichman Laboratory for Advanced Cancer Research, Memorial Sloan Kettering Cancer Institute for Cancer Research. Dr. Moore is also the attending biologist, Division of Medical Oncology, Hematology, Lymphoma Services, Memorial Sloan Kettering Cancer Center. Dr. Moore is an expert in hematology research and hematopoeitic stem cell growth, differentiation, and mobilization. His work in the early 1980s led to the advancement of G-CSF (Neupogen®) as a therapeutic product for stem cell growth and differentiation. Other notable contributions include the development of methods for induction and long-term maintenance of Thy-1 lymphocytes, erythropoeitin and stem cell factor. Dr. Moore is a member of the American Association of Immunologists, the American Society of Hematologists, the American Association for Cancer Research, the Cell Proliferation Society, and the International Society of Experimental Hematology. Dr. Moore is the winner of the following awards: Professor F. Takaku Award, Molecular Biology of Haematopoiesis, Excellence of Achievement Award of Haematopoiesis, 50th Anniversary Commemorative Award of the Leukemia Society of America, The Kurth Reissman Memorial Award, William Coley Award for Distinguished Research in Immunology and Van Bekkum Stem Cell Award. Dr. Moore is an advisor to: the National Cancer Institute, leukemia, lymphoma and myeloma Progress Review Group, Advanced Cell Technology, Inc., NaPro Biotherapeutics, Inc. and StemCo Biomedical Inc.

Louis M. Pelus, Ph.D.

Dr. Pelus has served as our medical advisor since July 2002. Dr. Pelus is the Associate Director of the Walther Oncology Center and an Associate Professor of Microbiology and Immunology at the Indiana University Medical School, Indianapolis, Indiana. Prior to joining Indiana University and Walther Oncology Center, Dr. Pelus held the position of Associate Director in Molecular Virology and Immunology at SmithKline Beecham Corp. ("SKB"), Pennsylvania. From 1991 to 1998 at SKB, Dr. Pelus discovered and developed a number of novel biotechnology products for control of differentiation and proliferation of normal and leukemic myeloid progenitor cells. Dr. Pelus is an expert in the field of chemokine and matrix metalloproteinases, and their association with the hematopoeitic stem cell mobilization. Dr. Pelus was the first to discover the peripheral blood stem cell regulation of growth and differentiation by CXC chemokine (GRO beta and GRO beta T). Dr. Pelus has published over one hundred peer reviewed scientific articles and book chapters and he is a member of the American Society of Hematology, of the American Association of Immunologists and of the International Society of Hematotherapy and Graft Engineering.

Fabio Rossi, Ph.D.

Dr. Fabio Rossi has served as our medical advisor since October 2005. Currently an assistant professor in Medical Genetics at the University of British Columbia, Dr. Rossi has extensive knowledge in medical genetics and medicine. Specializing in Molecular Biology and Medicine, Dr. Rossi carries a wide array of experience from all over North America. In 1991, Dr. Rossi received his Medical Doctorate with Honors from the University of Geneva, in Italy in the area of medicine. He then received his Ph.D. from the European Molecular Biology Laboratories in Heidelberg, Germany in Molecular Biology in 1996. Dr. Rossi is a member of the Italian Medical Professional Order, a habilitation to practice in the medical profession field. For five years he has supervised over eight graduate students at the University of British Columbia. He has been a presenter in over thirty presentations around the world, and has over twenty five publications. With over seven awards awarded to him such as the Canadian Research Chair 2001 award, and the Canadian Society for Clinical Investigation Award in 2005, Dr. Rossi brings a plethora of experience and knowledge to Chemokine Therapeutics Corp.